Tobira Therapeutics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Tobira Therapeutics sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).
Tobira Therapeutics: 11 sponsored US clinical trials, none currently recruiting.
Tobira Therapeutics sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 1 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Nonalcoholic Steatohepatitis, with 1 trials.
Top-decile sponsor footprint
Tobira Therapeutics ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
9 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
11 total, page 1 of 1
AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)
NCT03028740
Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis
NCT03059446
PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis
NCT02653625
Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination
NCT02684799
Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin
NCT02685462
ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD
NCT02330549
Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination
NCT02342067
Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis
NCT02217475
Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment
NCT02120547
Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam
NCT01827540
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
NCT01338883
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 5 |
| Phase 3 | 1 |
Therapeutic Areas
How the Tobira Therapeutics early-phase archive is shaped
11 indexed studies, none listed as recruiting (0% open); 9 completed (82%).
Phase mix: 1 late (III/IV) vs 10 early (I/II) (early-phase heavy).
Top condition: Nonalcoholic Steatohepatitis (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Tobira Therapeutics: archived-pipeline peers nationwide
Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Tobira Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 11 archived trials
- Aderans Research Institute · 11 trials · 0% recruiting
- Aegerion Pharmaceuticals · 11 trials · 0% recruiting
- Allena Pharmaceuticals · 11 trials · 0% recruiting
- AOBiome · 11 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Tobira Therapeutics page
11 registered trials is a research-attention snapshot, not an endorsement of Tobira Therapeutics or any single study.
- None of Tobira Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Nonalcoholic Steatohepatitis is the condition Tobira Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Nonalcoholic Steatohepatitis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Tobira Therapeutics pipeline card: 11 registered trials from official public datasets.Report a data error.